ArticleEuropean journal of heart failure2025
Computational modelling of myocardial metabolism in patients with advanced heart failure.
Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Why the septum thickens in hypertrophic cardiomyopathy.Journal of molecular and cellular cardiology plus · 2026Review
- Comparative analysis of metabolic and functional cardiac alterations in diet- and genetically induced mouse models of cardiac dysfunction.The FEBS journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
aimsPerturbations of myocardial metabolism and energy depletion are well-established hallmarks of heart failure (HF), yet methods for their systematic assessment remain limited in humans. This study aimed to determine the ability of computational modelling of patient-specific myocardial metabolism to assess individual bioenergetic phenotypes and their clinical implications in HF. METHODS AND
resultsBased on proteomics-derived enzyme quantities in 136 cardiac biopsies, personalised computational models of myocardial metabolism were generated in two independent cohorts of advanced HF patients together with sex- and body mass index-matched non-failing controls. The bioenergetic impact of dynamic changes in substrate availability and myocardial workload were simulated, and the models' ability to predict the myocardial response following left ventricular assist device (LVAD) implantation was assessed. Compared to controls, HF patients had a reduced ATP production capacity (p < 0.01), although there was remarkable interindividual variance. Utilisation of glucose relative to fatty acids was generally higher in HF patients, depending on substrate availability and myocardial workload. The ratio of fatty acid to glucose utilisation was associated with reverse cardiac remodelling after LVAD implantation and highly predictive of an improvement in left ventricular ejection fraction ≥10% (C-index 0.94 [0.81-1.00], p < 0.01). System-level simulations identified fatty acid administration and carnitine supplementation in those with low mitochondrial carnitine content as potential pharmacological interventions to restore myocardial substrate utilisation.
conclusionsComputational modelling identified a subset of advanced HF patients with preserved myocardial metabolism despite a similar degree of systolic dysfunction. Substrate preference was associated with the myocardial response after LVAD implantation, which suggests a role for substrate manipulation as a therapeutic approach. Computational assessment of myocardial metabolism in HF may improve understanding of disease heterogeneity, individual risk stratification, and guidance of personalised clinical decision-making in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.